Quantum Capital Management purchased a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 47,090 shares of the medical device company’s stock, valued at approximately $1,053,000. Quantum Capital Management owned about 0.14% of AtriCure at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in ATRC. Neuberger Berman Group LLC grew its stake in shares of AtriCure by 45.5% during the second quarter. Neuberger Berman Group LLC now owns 824,469 shares of the medical device company’s stock valued at $19,993,000 after purchasing an additional 257,949 shares during the last quarter. FMR LLC grew its stake in shares of AtriCure by 2.4% during the second quarter. FMR LLC now owns 5,068,247 shares of the medical device company’s stock valued at $122,905,000 after purchasing an additional 118,247 shares during the last quarter. Vanguard Group Inc. lifted its holdings in AtriCure by 5.7% in the first quarter. Vanguard Group Inc. now owns 1,393,971 shares of the medical device company’s stock valued at $26,695,000 after buying an additional 75,266 shares during the period. Marshall Wace North America L.P. acquired a new position in AtriCure in the second quarter valued at approximately $1,120,000. Finally, Royce & Associates LP lifted its holdings in AtriCure by 12.7% in the second quarter. Royce & Associates LP now owns 302,400 shares of the medical device company’s stock valued at $7,333,000 after buying an additional 34,100 shares during the period. 81.11% of the stock is currently owned by institutional investors and hedge funds.
AtriCure, Inc. (NASDAQ:ATRC) traded up $0.16 on Friday, reaching $18.33. 29,014 shares of the company’s stock traded hands, compared to its average volume of 201,018. The company has a current ratio of 2.28, a quick ratio of 1.65 and a debt-to-equity ratio of 0.20. AtriCure, Inc. has a 12 month low of $14.78 and a 12 month high of $25.18.
AtriCure (NASDAQ:ATRC) last posted its earnings results on Wednesday, November 1st. The medical device company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. The company had revenue of $42.20 million for the quarter, compared to analyst estimates of $43.44 million. AtriCure had a negative net margin of 19.40% and a negative return on equity of 20.28%. The business’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period last year, the business posted ($0.21) earnings per share. research analysts predict that AtriCure, Inc. will post -0.96 earnings per share for the current year.
In other AtriCure news, Director Elizabeth D. Krell sold 10,000 shares of the stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $22.40, for a total value of $224,000.00. Following the sale, the director now directly owns 29,967 shares in the company, valued at $671,260.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director B Kristine Johnson acquired 1,500 shares of the stock in a transaction dated Wednesday, November 8th. The shares were bought at an average cost of $18.36 per share, with a total value of $27,540.00. Following the transaction, the director now directly owns 10,969 shares of the company’s stock, valued at $201,390.84. The disclosure for this purchase can be found here. Company insiders own 10.00% of the company’s stock.
Several equities analysts recently weighed in on ATRC shares. Zacks Investment Research lowered shares of AtriCure from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. Needham & Company LLC cut their price objective on shares of AtriCure from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, November 2nd. Canaccord Genuity cut their price objective on shares of AtriCure from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, November 2nd. ValuEngine lowered shares of AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, BidaskClub lowered shares of AtriCure from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $25.00.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.